Literature DB >> 27152762

Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases.

Hung Nguyen1, David Aum1, Sherwin Mashkouri1, Gautam Rao1, Juan Diego Vega Gonzales-Portillo1, Stephanny Reyes1, Cesario V Borlongan1.   

Abstract

INTRODUCTION: In recent years, accumulating evidence has demonstrated the key role of inflammation in the progression of cerebrovascular diseases. Inflammation can persist over prolonged period of time after the initial insult providing a wider therapeutic window. Despite the acute endogenous upregulation of many growth factors after the injury, it is not sufficient to protect against inflammation and to regenerate the brain. Therapeutic approaches targeting both dampening inflammation and enhancing growth factors are likely to provide beneficial outcomes in cerebrovascular disease. AREAS COVERED: In this mini review, we discuss major growth factors and their beneficial properties to combat the inflammation in cerebrovascular diseases. Emerging biotechnologies which facilitate the therapeutic effects of growth factors are also presented in an effort to provide insights into the future combination therapies incorporating both central and peripheral abrogation of inflammation. Expert commentary: Many studies discussed in this review have demonstrated the therapeutic effects of growth factors in treating cerebrovascular diseases. It is unlikely that one growth factor can be used to treat these complex diseases. Combination of growth factors and anti-inflammatory modulators may clinically improve outcomes for patients. In particular, transplantation of stem cells may be able to achieve both goals of modulating inflammation and upregulating growth factors. Large preclinical studies and multiple laboratory collaborations are needed to advance these findings from bench to bedside.

Entities:  

Keywords:  Cerebral ischemia; biomedical engineering; growth factors; inflammation; neuroprotection; stem cells; trauma

Mesh:

Substances:

Year:  2016        PMID: 27152762      PMCID: PMC5057178          DOI: 10.1080/14737175.2016.1184086

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  137 in total

1.  Chemokine signaling: rules of attraction.

Authors:  Alexander F Schier
Journal:  Curr Biol       Date:  2003-03-04       Impact factor: 10.834

2.  Genetic variant of BDNF (Val66Met) polymorphism attenuates stroke-induced angiogenic responses by enhancing anti-angiogenic mediator CD36 expression.

Authors:  Luye Qin; Eunhee Kim; Rajiv Ratan; Francis S Lee; Sunghee Cho
Journal:  J Neurosci       Date:  2011-01-12       Impact factor: 6.167

Review 3.  A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review.

Authors:  Michael Notaras; Rachel Hill; Maarten van den Buuse
Journal:  Neurosci Biobehav Rev       Date:  2015-01-03       Impact factor: 8.989

4.  Biosynthesis and post-translational processing of the precursor to brain-derived neurotrophic factor.

Authors:  S J Mowla; H F Farhadi; S Pareek; J K Atwal; S J Morris; N G Seidah; R A Murphy
Journal:  J Biol Chem       Date:  2001-01-10       Impact factor: 5.157

5.  Stem cell factor and granulocyte colony-stimulating factor exhibit therapeutic effects in a mouse model of CADASIL.

Authors:  Xiao-Yun Liu; Maria E Gonzalez-Toledo; Austin Fagan; Wei-Ming Duan; Yanying Liu; Siyuan Zhang; Bin Li; Chun-Shu Piao; Lila Nelson; Li-Ru Zhao
Journal:  Neurobiol Dis       Date:  2014-09-22       Impact factor: 5.996

6.  Expansion of the dentate mossy fiber-CA3 projection in the brain-derived neurotrophic factor-enriched mouse hippocampus.

Authors:  C Isgor; C Pare; B McDole; P Coombs; K Guthrie
Journal:  Neuroscience       Date:  2014-12-31       Impact factor: 3.590

7.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

8.  Systemically administered brain-targeted nanoparticles transport peptides across the blood-brain barrier and provide neuroprotection.

Authors:  Muge Yemisci; Secil Caban; Yasemin Gursoy-Ozdemir; Sevda Lule; Ramon Novoa-Carballal; Ricardo Riguera; Eduardo Fernandez-Megia; Karine Andrieux; Partick Couvreur; Yilmaz Capan; Turgay Dalkara
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

9.  Umbilical cord mesenchymal stem cell transplantation significantly improves neurological function in patients with sequelae of traumatic brain injury.

Authors:  Sen Wang; Hongbin Cheng; Guanghui Dai; Xiaodong Wang; Rongrong Hua; Xuebin Liu; Peishen Wang; Guangming Chen; Wu Yue; Yihua An
Journal:  Brain Res       Date:  2013-08-11       Impact factor: 3.252

Review 10.  Growth factors for the treatment of ischemic brain injury (growth factor treatment).

Authors:  Amara Larpthaveesarp; Donna M Ferriero; Fernando F Gonzalez
Journal:  Brain Sci       Date:  2015-04-30
View more
  9 in total

1.  The brain and eye: Treating cerebral and retinal ischemia through mitochondrial transfer.

Authors:  Matt Heyck; Brooke Bonsack; Henry Zhang; Nadia Sadanandan; Blaise Cozene; Chase Kingsbury; Jea-Young Lee; Cesar V Borlongan
Journal:  Exp Biol Med (Maywood)       Date:  2019-10-11

2.  Inflammatory cytokines and cells are potential markers for patients with cerebral apoplexy in intensive care unit.

Authors:  Jianhong Wang; Zicheng Hu; Shu Yang; Chengchun Liu; Haimei Yang; Duozi Wang; Fuqiang Guo
Journal:  Exp Ther Med       Date:  2018-05-23       Impact factor: 2.447

Review 3.  Therapeutic Potential of Cytokines in Demyelinating Lesions After Stroke.

Authors:  Yi-Sha Guo; Mei Yuan; Yu Han; Xin-Ya Shen; Zhen-Kun Gao; Xia Bi
Journal:  J Mol Neurosci       Date:  2021-05-10       Impact factor: 3.444

Review 4.  Concise Review: Stem Cell Therapy for Stroke Patients: Are We There Yet?

Authors:  Cesario V Borlongan
Journal:  Stem Cells Transl Med       Date:  2019-05-16       Impact factor: 6.940

5.  Eye Opener in Stroke.

Authors:  Hung Nguyen; Jea Young Lee; Paul R Sanberg; Eleonora Napoli; Cesar V Borlongan
Journal:  Stroke       Date:  2019-06-27       Impact factor: 10.170

6.  Prophylactic treatment of hyperbaric oxygen treatment mitigates inflammatory response via mitochondria transfer.

Authors:  Trenton Lippert; Cesario V Borlongan
Journal:  CNS Neurosci Ther       Date:  2019-04-11       Impact factor: 5.243

7.  Sufentanil alleviates cerebral ischemia-reperfusion injury by inhibiting inflammation and protecting the blood-brain barrier in rats.

Authors:  Zhen Wang; Xiaoyan Du; Daoyang Yu; Yang Yang; Gaoen Ma; Xueli Jia; Lulu Cheng
Journal:  Eur J Histochem       Date:  2022-01-12       Impact factor: 3.188

Review 8.  Cell therapy for central nervous system disorders: Current obstacles to progress.

Authors:  Takao Yasuhara; Satoshi Kawauchi; Kyohei Kin; Jun Morimoto; Masahiro Kameda; Tatsuya Sasaki; Brooke Bonsack; Chase Kingsbury; Naoki Tajiri; Cesario V Borlongan; Isao Date
Journal:  CNS Neurosci Ther       Date:  2019-10-17       Impact factor: 5.243

Review 9.  Hyperbaric oxygen therapy: A new look on treating stroke and traumatic brain injury.

Authors:  Bella Gonzales-Portillo; Trenton Lippert; Hung Nguyen; Jea-Young Lee; Cesar V Borlongan
Journal:  Brain Circ       Date:  2019-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.